Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01351103 | A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands | PHASE1 | COMPLETED | 185 | — | — | Dec 1, 2011 | Jun 17, 2024 | Jun 13, 2025 | 20 | United States, Canada +5 |
DLT is defined as an adverse event or abnormal laboratory value that is assessed by the investigator as unrelated to disease, disease progression, intercurrent illness, or concomitant medications and that meets the criteria defined in the study protocol. The objective was to determine the Maximum Tolerated Dose (MTD) or Recommended Dose for Expansion (RDE) of LGK974 as a single agent and in combination with PDR001 when administered orally to adult patients with malignancies dependent on Wnt ligands.
| Arm | Type | Description |
|---|---|---|
| LGK974 | EXPERIMENTAL | LGK974 |
| LGK974 in combination with PDR001 | EXPERIMENTAL | LGK in combination with PDR001 |
| Name | Type | Description |
|---|---|---|
| LGK974 | DRUG | - |
| PDR001 | BIOLOGICAL | - |
Inclusion Criteria: Diagnosis of locally advanced or metastatic cancer that has progressed despite standard therapy or for which no effective standard therapy exists and histological confirmation of one of the following diseases indicated below: Single Agent Dose escalation part:documented B-RAF m...